Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $114.79 USD
Change Today -2.64 / -2.25%
Volume 8.2M
AET On Other Exchanges
Symbol
Exchange
New York
As of 2:53 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

aetna inc (AET) Key Developments

Aetna Seeking Divestitures

Mark Bertolini, Chief Executive of Aetna Inc. (NYSE:AET) addressed antitrust concerns over acquisition of Humana Inc. (NYSE:HUM) and said that Aetna had already prepared for possible divestitures to address overlaps with Humana's business. "We took a conservative view of what we would need to divest," Bertolini said.

Aetna Inc., Humana Inc. - M&A Call

To consider definitive agreement under which Aetna will acquire all outstanding shares of Humana for a combination of cash and stock valued at $37 billion or approximately $230 per Humana share based on the closing price of Aetna common shares on July 2, 2015

Aetna Inc. Announces Management Changes

Sharon A. Virag will be appointed as Vice President, Controller and Chief Accounting Officer of Aetna Inc. effective July 3, 2015. Ms. Virag will succeed Rajan Parmeswar who, as previously announced, will be leaving Aetna effective July 3, 2015. Ms. Virag, age 49, is a certified public accountant and joined Aetna as Vice President, Corporate Finance on June 1, 2015. Prior to joining Aetna, Ms. Virag served as Vice President and Controller (Chief Accounting Officer) of The AES Corporation, a position she held since May 2013. Prior to AES, she was the Global Controller for the General Electric Oil & Gas Division and served as the Global Controller for GE Power & Water since 2010. Prior to joining GE, Ms. Virag held multiple posts, both domestic and international, at General Motors Company from 2008 to 2010, including Assistant Corporate Controller; Controller, GM Asia/Pacific; and Director of Internal Control and Sox Compliance.

The University of Chicago Medicine and Aetna Inc. Form Oncology Medical Home

The University of Chicago Medicine and Aetna Inc. announced a collaboration to create an oncology medical home that is designed to improve the care experience for cancer patients. This approach allows teams of cancer specialists to work together to care for a patient with a cancer diagnosis. The model will give UChicago Medicine the responsibility to arrange appropriate care that is continuous and proactive. The model is part of a strategic decision to transition from fee-for-service reimbursement to value-based payment. Value-based arrangements are emerging as a solution to address rising health care costs, clinical inefficiency and duplication of services. These arrangements also make it easier for people to get the care they need. In value-based models, doctors and hospitals are paid for helping keep people healthy and for improving the health of those who have chronic conditions in an evidence-based, cost-effective way. The operating principles of the UChicago Medicine and Aetna oncology medical home include: An orientation to the whole person; Evidence-based, personalized medical care; Coordinated and integrated care; Quality and safety; Enhanced access to care. The oncology medical home arrangement begins on July 1, 2015.

Veracyte, Inc. Announces National Network Agreement with Aetna

Veracyte Inc. announced that it has signed an agreement to become part of Aetna's laboratory network, effective July 1, 2015. Veracyte administers the Afirma Thyroid FNA analysis, a proprietary Gene Expression Classifier (GEC) test. The test is used as part of thyroid cancer diagnosis when it is medically necessary to identify benign thyroid nodules among those deemed indeterminate by cytopathology, potentially enabling patients to avoid an unnecessary surgery.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AET:US $114.81 USD -2.62

AET Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Anthem Inc $160.15 USD -1.45
Cigna Corp $152.87 USD -7.19
Humana Inc $186.44 USD -2.52
MetLife Inc $55.33 USD -0.58
Prudential Financial Inc $86.38 USD -1.13
View Industry Companies
 

Industry Analysis

AET

Industry Average

Valuation AET Industry Range
Price/Earnings 19.4x
Price/Sales 0.7x
Price/Book 2.7x
Price/Cash Flow 17.1x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETNA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.